Differential effects of metabolic inhibitors on cytoplasmic membrane associated and nuclear DNA.
D000963:Antimetabolites / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000494:pharmacology; D001692:Biological Transport; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002250:Carbon Radioisotopes; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism*; D002499:Centrifugation, Density Gradient; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis / Q000378:metabolism*; D004996:Ethidium / Q000494:pharmacology; D005467:Floxuridine / Q000494:pharmacology; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D012293:Rifampin / Q000031:analogs & derivatives / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D000963:Antimetabolites; D001593:Benzyl Compounds; D002250:Carbon Radioisotopes; D005467:Floxuridine; D003561:Cytarabine; D004247:DNA; D004996:Ethidium; D001973:Bromodeoxyuridine; D013936:Thymidine; D012293:Rifampin; D006918:Hydroxyurea